Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
54.14
-1.41 (-2.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,345,749
Open
55.55
Bid (Size)
54.13 (2,200)
Ask (Size)
54.15 (300)
Prev. Close
55.55
Today's Range
54.10 - 55.60
52wk Range
50.76 - 73.18
Shares Outstanding
183,352,255
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
March 26, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via
StockStory
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
↗
March 20, 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
-8.9%
-8.9%
1 Month
-13.5%
-13.5%
3 Month
-9.7%
-9.7%
6 Month
+2.9%
+2.9%
1 Year
-24.3%
-24.3%
More News
Read More
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
↗
March 20, 2026
Via
The Motley Fool
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case
↗
March 16, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss
↗
February 23, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case
↗
January 24, 2026
Via
Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate
↗
January 02, 2026
Via
Chartmill
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
March 19, 2026
Via
StockStory
Topics
Artificial Intelligence
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
↗
March 16, 2026
Via
The Motley Fool
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
↗
March 16, 2026
Via
The Motley Fool
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
↗
March 15, 2026
Via
The Motley Fool
2 Mid-Cap Stocks with Exciting Potential and 1 We Question
March 12, 2026
Via
StockStory
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
↗
March 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
2 Reasons to Like BMRN (and 1 Not So Much)
March 02, 2026
Via
StockStory
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates
February 23, 2026
Via
StockStory
Topics
Earnings
BioMarin Pharmaceutical Earnings: What To Look For From BMRN
February 21, 2026
Via
StockStory
Topics
Artificial Intelligence
Government
World Trade
Should You Buy BioMarin Pharmaceutical Before Feb. 18?
↗
January 31, 2026
Via
The Motley Fool
Topics
Earnings
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky
January 08, 2026
Via
StockStory
Topics
Artificial Intelligence
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
January 06, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
10 Magnificent Stocks That Can Make You Richer in 2026
↗
January 05, 2026
Via
The Motley Fool
Topics
Economy
Stocks
World Trade
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
December 29, 2025
Via
MarketMinute
Topics
ETFs
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq
December 23, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Frequently Asked Questions
Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?
Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.
What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?
BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?
The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market
What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?
The current price of BioMarin Pharmaceutical Inc. - Common Stock is 54.14
When was BioMarin Pharmaceutical Inc. - Common Stock last traded?
The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 03/27/26 04:00 PM ET
What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?
The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 9.93B
How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?
BioMarin Pharmaceutical Inc. - Common Stock has 10B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
